CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer

BACKGROUND: Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival in ovarian cancer and a characteristic of the immunoreactive subtype, which predicts ICB response. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Seitz, Stefanie, Dreyer, Tobias F., Stange, Christoph, Steiger, Katja, Bräuer, Rosalinde, Scheutz, Leandra, Multhoff, Gabriele, Weichert, Wilko, Kiechle, Marion, Magdolen, Viktor, Bronger, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090786/
https://www.ncbi.nlm.nih.gov/pubmed/35314795
http://dx.doi.org/10.1038/s41416-022-01763-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090786/
https://www.ncbi.nlm.nih.gov/pubmed/35314795
http://dx.doi.org/10.1038/s41416-022-01763-0

Ejemplares similares